The FDA has scheduled a meeting of the Psychopharmacologic Drug Advisory Committee for February 16, 2016. The Committee will discuss new drug application (NDA) 209241, Valbenazine 40 mg capsules, for the proposed treatment of Tardive Dyskinesia, submitted by Neurocrine Biosciences, Inc.
See the announcement